InnoPharmax Inc. (TPEX:4172)
Taiwan · Delayed Price · Currency is TWD 11.15
-0.30 (-2.62%)
Aug 19, 2026, 1:52 PM CST
InnoPharmax Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 67.47 | 68.99 | 32.3 | 46.07 | 29.13 | 48.06 |
Revenue Growth | -2.20% | 113.60% | -29.90% | 58.15% | -39.38% | -64.89% |
Gross Profit Gross Profit Growth | 13.22 | 9.83 | 20.76 | 17.46 | -0.38 | 7.41 |
Operating Income Operating Income Growth | -192.83 | -171.76 | -95.98 | -64.84 | -93.33 | -74.37 |
Net Income Net Income Growth | -203.65 | -184.4 | -99.29 | -70.83 | -103.18 | -92.97 |
Earnings Per Share EPS Growth | -1.82 | -1.71 | -1.02 | -0.77 | -1.19 | -1.08 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Taiwan Taiwan Growth | 27.87 | 27.87 | 23.38 | 28.56 | 29.13 | 40.59 |
Mainland China Mainland China Growth | 32.85 | 32.85 | 8.92 | 16.54 | - | 3.58 |
Others Others Growth | 8.26 | 8.26 | - | 0.98 | - | 3.89 |
Total Total Growth | 68.99 | 68.99 | 32.3 | 46.07 | 29.13 | 48.06 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 263.77 | 146.28 | 281.23 | 139.66 | 96.37 | 187.26 |
Total Debt Total Debt Growth | 11.8 | 10.82 | 15.39 | 21.36 | 37.56 | 5.57 |
Net Cash (Debt) Net Cash Growth | 251.98 | 135.46 | 265.84 | 118.29 | 58.82 | 181.69 |
Net Cash Growth | 86.01% | -49.04% | 124.73% | 101.12% | -67.63% | -14.29% |
Net Cash Per Share Net Cash Per Share Growth | 2.25 | 1.26 | 2.73 | 1.28 | 0.68 | 2.10 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -150.79 | -134.19 | -76.22 | -48.57 | -100.08 | -50.03 |
Capital Expenditures CapEx Growth | -0.28 | -0.28 | -0.53 | -0.4 | - | -1.45 |
Free Cash Flow Free Cash Flow Growth | -151.06 | -134.47 | -76.75 | -48.97 | -100.08 | -51.48 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 19.60% | 14.25% | 64.29% | 37.89% | -1.29% | 15.43% |
Operating Margin | -285.80% | -248.98% | -297.18% | -140.73% | -320.35% | -154.76% |
Pretax Margin | -296.64% | -262.21% | -300.23% | -153.74% | -354.17% | -193.44% |
Profit Margin | -301.84% | -267.29% | -307.43% | -153.74% | -354.17% | -193.44% |
FCF Margin | -223.90% | -194.92% | -237.64% | -106.29% | -343.51% | -107.11% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 19, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Forward PE | - | 8.65 | 8.65 | 8.65 | 8.65 | 8.65 |
PS Ratio | 17.70 | 26.20 | 54.13 | 35.88 | 34.87 | 31.40 |